Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19

NCT05065645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

DRUG: Angiotensin Converting Enzyme 2
DRUG: Sodium chloride

Sponsor

Apeiron Biologics

Collaborators

[object Object]